BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dewailly D, Barbotin AL, Dumont A, Catteau-Jonard S, Robin G. Role of Anti-Müllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome. Front Endocrinol (Lausanne) 2020;11:641. [PMID: 33013710 DOI: 10.3389/fendo.2020.00641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Zhai Y, Li L, Lu Y, Su S, Liu Y, Xu Z, Xin M, Zhang Q, Cao Z. Divergent Associations Between Serum Androgens and Ovarian Reserve Markers Revealed in Patients With Polycystic Ovary Syndrome. Front Endocrinol (Lausanne) 2022;13:881740. [PMID: 35757414 DOI: 10.3389/fendo.2022.881740] [Reference Citation Analysis]
2 Abruzzese GA, Silva AF, Velazquez ME, Ferrer MJ, Motta AB. Hyperandrogenism and Polycystic ovary syndrome: Effects in pregnancy and offspring development. WIREs Mech Dis 2022;:e1558. [PMID: 35475329 DOI: 10.1002/wsbm.1558] [Reference Citation Analysis]
3 Garg A, Patel B, Abbara A, Dhillo WS. Treatments targeting neuroendocrine dysfunction in polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2022. [PMID: 35262967 DOI: 10.1111/cen.14704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bertho S, Neyroud AS, Brun T, Jaillard S, Bonnet F, Ravel C. Anti-Müllerian hormone: A function beyond the Müllerian structures. Morphologie 2021:S1286-0115(21)00251-4. [PMID: 34924282 DOI: 10.1016/j.morpho.2021.11.002] [Reference Citation Analysis]
5 Shang Y, Zhou H, He R, Lu W. Dietary Modification for Reproductive Health in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:735954. [PMID: 34790167 DOI: 10.3389/fendo.2021.735954] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Bell RJ, Islam RM, Skiba MA, Herbert D, Martinez Garcia A, Davis SR. Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study. Hum Reprod 2021:deab232. [PMID: 34741176 DOI: 10.1093/humrep/deab232] [Reference Citation Analysis]
7 Guo Y, Liu S, Hu S, Li F, Jin L. High Serum Anti-Müllerian Hormone Concentrations Are Associated With Poor Pregnancy Outcome in Fresh IVF/ICSI Cycle but Not Cumulative Live Birth Rate in PCOS Patients. Front Endocrinol (Lausanne) 2021;12:673284. [PMID: 34122349 DOI: 10.3389/fendo.2021.673284] [Reference Citation Analysis]
8 Pugeat M, Dewailly D. Epigenetics suggests new perspectives for the treatment of polycystic ovary syndrome: Transgenerational effect of fetal exposure to Antimüllerian Hormone. Ann Endocrinol (Paris) 2021;82:71-3. [PMID: 33839124 DOI: 10.1016/j.ando.2021.04.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Pérez-López FR, Ornat L, López-Baena MT, Santabárbara J, Savirón-Cornudella R, Pérez-Roncero GR. Circulating kisspeptin and anti-müllerian hormone levels, and insulin resistance in women with polycystic ovary syndrome: A systematic review, meta-analysis, and meta-regression. Eur J Obstet Gynecol Reprod Biol 2021;260:85-98. [PMID: 33744505 DOI: 10.1016/j.ejogrb.2021.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wu Z, Fang L, Li Y, Yan Y, Thakur A, Cheng JC, Sun YP. Association of circulating monocyte chemoattractant protein-1 levels with polycystic ovary syndrome: A meta-analysis. Am J Reprod Immunol 2021;86:e13407. [PMID: 33638245 DOI: 10.1111/aji.13407] [Cited by in F6Publishing: 1] [Reference Citation Analysis]